(Q43899942)

27 November 2017

Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin (English)

1 reference

27 November 2017

1 reference

2

1 reference

27 November 2017

John G McHutchison

1

1 reference

27 November 2017

Rafael Esteban-Mur

3

1 reference

27 November 2017

Gary L Davis

4

1 reference

27 November 2017

Zachary D Goodman

5

1 reference

27 November 2017

Joann Harvey

6

1 reference

27 November 2017

Mei-Hsiu Ling

7

1 reference

27 November 2017

Jean Jacques Garaud

8

1 reference

27 November 2017

Janice K Albrecht

9

1 reference

27 November 2017

Keyur Patel

10

1 reference

27 November 2017

Jules L Dienstag

11

1 reference

27 November 2017

Timothy Morgan

12

1 reference

27 November 2017

International Hepatitis Interventional Therapy Group

13

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

27 November 2017

1 reference

27 November 2017

35

1 reference

27 November 2017

3

1 reference

27 November 2017

688-693

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

27 November 2017

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Factors predictive of a beneficial response to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Long-term course of interferon-treated chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

Distribution of markers of hepatitis C virus infection throughout the body

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.31870

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.31870

1 reference

27 November 2017

1 reference